Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study.

Analytical chemistry Analytical procedure validation GC–MS Inter-laboratory study LC-MS Mass spectrometry Nitrosamine

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
10 2023
Historique:
received: 14 04 2023
revised: 14 07 2023
accepted: 24 07 2023
medline: 18 9 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

With the discovery of carcinogenic nitrosamine impurities in pharmaceuticals in 2018 and subsequent regulatory requirements for risk assessment for nitrosamine formation during pharmaceutical manufacturing processes, storage or from contaminated supply chains, effective testing of nitrosamines has become essential to ensure the quality of drug substances and products. Mass spectrometry has been widely applied to detect and quantify trace amounts of nitrosamines in pharmaceuticals. As part of an effort by regulatory authorities to assess the measurement variation in the determination of nitrosamines, an inter-laboratory study was performed by the laboratories from six regulatory agencies with each of the participants using their own analytical procedures to determine the amounts of nitrosamines in a set of identical samples. The results demonstrated that accurate and precise quantitation of trace level nitrosamines can be achieved across multiple analytical procedures and provided insight into the performance characteristics of mass spectrometry-based analytical procedures in terms of accuracy, repeatability and reproducibility.

Identifiants

pubmed: 37524228
pii: S0022-3549(23)00298-8
doi: 10.1016/j.xphs.2023.07.022
pii:
doi:

Substances chimiques

Nitrosamines 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2685-2695

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jingyue Yang (J)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.

Raghavi Kakarla (R)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.

Tim Marzan (T)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.

Bill Sherwin (B)

TGA Laboratories, 136 Narrabundah Lane, Symonston, Canberra, A.C.T 2606, Australia.

Mark George (M)

TGA Laboratories, 136 Narrabundah Lane, Symonston, Canberra, A.C.T 2606, Australia.

Justine Bennett (J)

TGA Laboratories, 136 Narrabundah Lane, Symonston, Canberra, A.C.T 2606, Australia.

Jose Basutto (J)

TGA Laboratories, 136 Narrabundah Lane, Symonston, Canberra, A.C.T 2606, Australia.

Yi Su (Y)

Health Products Laboratory Program, Regulatory Operations and Enforcement Branch, Department of Health, Government of Canada, 2301 Midland Ave, Toronto ON, M1P 4R7, Canada.

Jason Ollerenshaw (J)

Health Products Laboratory Program, Regulatory Operations and Enforcement Branch, Department of Health, Government of Canada, 2301 Midland Ave, Toronto ON, M1P 4R7, Canada.

Justin Morin (J)

Health Products Laboratory Program, Regulatory Operations and Enforcement Branch, Department of Health, Government of Canada, 2301 Midland Ave, Toronto ON, M1P 4R7, Canada.

Hervé Rebière (H)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Annie-Francoise Maggio (AF)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Audrey Kermaïdic (A)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Elodie Gervela (E)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Charlotte Brenier (C)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Corinne Civade (C)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Denis Chauvey (D)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Françoise Duperray (F)

French National Agency for the Safety of Medicines and Health Products (ANSM), Laboratory Controls Division; 635 Rue de la Garenne, 34740 Vendargues, France.

Uwe Wollein (U)

Department of Pharmacy (OMCL), Bavarian Health and Food Safety Authority, Veterinaerstr. 2 85764 Oberschleissheim, Germany.

Massimiliano Conti (M)

Schweizerisches Heilmittelinstitut (Biol. & Pharm.), OMCL Swissmedic, Hallerstrasse 7, 3012, Bern, Switzerland.

Jan Tromp (J)

Schweizerisches Heilmittelinstitut (Biol. & Pharm.), OMCL Swissmedic, Hallerstrasse 7, 3012, Bern, Switzerland.

Simon Meyer (S)

Schweizerisches Heilmittelinstitut (Biol. & Pharm.), OMCL Swissmedic, Hallerstrasse 7, 3012, Bern, Switzerland.

Richard Wanko (R)

Biological Standardisation, OMCL Network & HealthCare Department (DBO), EDQM - Council of Europe - Conseil de l'Europe, 7 Allée Kastner CS 30026 F- 67081 Strasbourg, France.

Michael Wierer (M)

Biological Standardisation, OMCL Network & HealthCare Department (DBO), EDQM - Council of Europe - Conseil de l'Europe, 7 Allée Kastner CS 30026 F- 67081 Strasbourg, France.

Marie Bertrand (M)

Biological Standardisation, OMCL Network & HealthCare Department (DBO), EDQM - Council of Europe - Conseil de l'Europe, 7 Allée Kastner CS 30026 F- 67081 Strasbourg, France.

Jason Rodriguez (J)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.

Cynthia Sommers (C)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.

David Keire (D)

Office of Testing and Research, Center of Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA. Electronic address: david.keire@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH